Axios AI & Machine LearningDoubao · 实盘不做把握 8/10不做原因:无可交易标的
北京时间·🕒 发布 22:32:27·⟳ 抓取 22:35:19 +2m52s·⚡ 决策 10-13 22:48:25 +13m06s·13.8 天前
AI生物科技公司Iambic本周推进美股IPO，但标的尚未开始交易，暂无可执行证券
核心公司Iambic尚未挂牌，Nasdaq明确显示IAM当前未交易；Isomorphic为私有公司，Alphabet及RXRX/SDGR只具间接或情绪联动，缺乏可执行且有正期望的交易载体。
📄 原文Axios AI & Machine Learning↗ 原文
The drug disconnect between Iambic and Isomorphic
Wall Street is scratching its head over Iambic Therapeutics, an AI biotech that plans to go public this week. The big p…
不做 Iambic Therapeutics（IAM.US）
IPO尚未定价且Nasdaq显示IAM当前未交易；虽有Duquesne/ARK需求和潜在提区间讨论，但当前没有可执行二级市场价格、流动性或止损条件。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
这是IPO前路演/定价评论，不是已上市证券的新增可交易催化。Iambic上市条款与明星买盘值得跟踪，但在实际定价、挂牌和首日流动性出现前不能下单。
消息传播链
- Axios在美股盘中发表Iambic IPO与Isomorphic估值差距分析，并称Iambic曾讨论是否上调目标区间；该文是评论和消息整合，不是公司正式提价公告。
关键理由
- Iambic上市进展和6,000万美元机构需求可能支持IPO定价，但当前只能参与一级分配，二级市场尚无成交载体。
- Isomorphic估值传闻或提升AI制药主题关注度，但对Alphabet、Recursion或Schrödinger均无直接、可量化的新增业绩影响。
主要风险
- 若Iambic正式上调发行区间并迅速挂牌，可能错过首日重评，但这类IPO首日波动无法在当前信号时点用可回测规则承接。
- Isomorphic融资尚未完成且估值差距巨大，若融资谈判落空或Iambic定价低于预期，AI制药联动标的可能反向波动。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-13 · 影响 weakens
Axios明确指出公开市场去年因Recursion和Schrödinger等计算药物发现挫折而受创，且Iambic仍处早期临床、定价未决，削弱追题材联动的理由。
检索:computational drug discovery public market setbacks Recursion Schrödinger Iambic IPO demand valuation risk 原文 ↗ - 做多前查反向 · 来源 web · 影响 invalidates
交易所页面显示IAM尚未交易，二级市场无法成交，直接否绝当前ENTER LONG的可执行性。
检索:IAM Iambic Therapeutics currently not trading Nasdaq 原文 ↗
先例如何影响了这次决策
对本次决策的影响:因无可交易主标的，先例不改变AVOID结论；待IAM实际挂牌后，应另行用同市场生物医药IPO首日先例校准买点和波动。
方向:未使用先例定价；本次决策的约束是核心标的尚未交易，而不是上市后方向判断。
涨幅量级:Recursion与Schrödinger的IPO或板块历史只能提供远期情绪参照，无法校准尚未挂牌的IAM首日开盘、成交和涨幅。
形态:文章本身提示计算药物发现二级市场曾因Recursion、Schrödinger挫折而承压，但这只是板块风险背景，不构成对RXRX或SDGR的事件交易信号。
工具执行结果 · 成功 8 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 13 ms
{"result": "search_processed_events:agent query=`iambic ai biotech roadshow ark duquesne ipo | iambic therapeutics ipo $160 million $900 million valuation | isomorphic labs $40 billion valuation fundraising bloomberg`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有 - web_search 成功 doubao_search · 1,767 ms
豆包搜索结果（原始查询:Iambic Therapeutics IPO ticker expected price range October 2026 $160 million $900 million；API SearchType:web） - web_search 成功 doubao_search · 195 ms
豆包搜索结果（原始查询:Isomorphic Labs funding $40 billion valuation Bloomberg October 2026；API SearchType:web） - web_search 成功 doubao_search · 1,275 ms
豆包搜索结果（原始查询:AI drug discovery IPO Recursion Schrödinger stock reaction comparable IPO first day performance；API SearchType:web） - web_search 成功 doubao_search · 739 ms
web_search「site:renaissancecapital.com/IPO-Center/News/122117 Iambic Therapeutics IAM Nasdaq terms 150 million」无结果。 - web_search 成功 doubao_search · 1,699 ms
豆包搜索结果（原始查询:Iambic Therapeutics Nasdaq IAM IPO expected pricing date prospectus；API SearchType:web） - web_search 成功 doubao_search · 1,332 ms
豆包搜索结果（原始查询:Iambic Therapeutics S-1 IPO competitors Isomorphic Labs ARK Duquesne 60 million；API SearchType:web） - direct_instrument_candidates 成功 stock_tools HTTP · 12 ms
{
原文全文
展开原文 · 2,386 字
Wall Street is scratching its head over Iambic Therapeutics, an AI biotech that plans to go public this week.
The big picture: Either it's the bargain of a lifetime or the private markets are wildly overvaluing one of its top comps, Alphabet-backed Isomorphic Labs.
Catch up quick: Iambic has developed a platform that it believes will be able to identify, develop and commercialize drugs using AI — a feat that thus far has been more dreamed than demonstrated.
- It has a cancer candidate in early clinical trials with over 100 patients, and two more Phase 1 trials in the near-term pipeline.
By the numbers: Iambic would raise around $160 million at a $900 million valuation were it to price at the top of its IPO range, after having raised around $350 million from venture capital firms.
- Around $60 million of the IPO shares would be purchased by Stan Druckenmiller's Duquesne Family Office and existing investor Cathie Wood's ARK Investment Management.
The intrigue: One of the companies identified by Iambic as a competitor is Isomorphic, led by Google DeepMind co-founder Demis Hassabis. It has not announced any clinical trials.
- Last Thursday — the same day that Iambic launched its IPO roadshow — there was a Bloomberg report that Isomorphic "is in early talks to raise new funds at a valuation of at least $40 billion."
Behind the scenes: A source tells me that Iambic was floored by the Isomorphic report, and discussed whether or not to raise its target range.
- No word yet on if that will happen, but don't be surprised if it does.
Zoom in: The valuation disconnect seems to be multi-pronged.
- First, there seems to be a Google/Demis Hassabis premium on Isomorphic. Even if Alphabet board member and Nobel Prize winner Frances Arnold is on Iambic's scientific advisory board.
- Second, Iambic's founding team is viewed as more bio-first, whereas Isomorphic's is viewed as more AI-first. And we all know which one investors currently value more.
- Third, the public markets last year got burned by computational drug discovery setbacks at companies like Recursion and Schrödinger. Iambic would argue that it has an entirely different platform, and promising early data, but it must leapfrog memories that Isomorphic's private market investors don't share.
The bottom line: Biotechs keep going public despite a narrowed IPO window, but pricing remains an open question.
The big picture: Either it's the bargain of a lifetime or the private markets are wildly overvaluing one of its top comps, Alphabet-backed Isomorphic Labs.
Catch up quick: Iambic has developed a platform that it believes will be able to identify, develop and commercialize drugs using AI — a feat that thus far has been more dreamed than demonstrated.
- It has a cancer candidate in early clinical trials with over 100 patients, and two more Phase 1 trials in the near-term pipeline.
By the numbers: Iambic would raise around $160 million at a $900 million valuation were it to price at the top of its IPO range, after having raised around $350 million from venture capital firms.
- Around $60 million of the IPO shares would be purchased by Stan Druckenmiller's Duquesne Family Office and existing investor Cathie Wood's ARK Investment Management.
The intrigue: One of the companies identified by Iambic as a competitor is Isomorphic, led by Google DeepMind co-founder Demis Hassabis. It has not announced any clinical trials.
- Last Thursday — the same day that Iambic launched its IPO roadshow — there was a Bloomberg report that Isomorphic "is in early talks to raise new funds at a valuation of at least $40 billion."
Behind the scenes: A source tells me that Iambic was floored by the Isomorphic report, and discussed whether or not to raise its target range.
- No word yet on if that will happen, but don't be surprised if it does.
Zoom in: The valuation disconnect seems to be multi-pronged.
- First, there seems to be a Google/Demis Hassabis premium on Isomorphic. Even if Alphabet board member and Nobel Prize winner Frances Arnold is on Iambic's scientific advisory board.
- Second, Iambic's founding team is viewed as more bio-first, whereas Isomorphic's is viewed as more AI-first. And we all know which one investors currently value more.
- Third, the public markets last year got burned by computational drug discovery setbacks at companies like Recursion and Schrödinger. Iambic would argue that it has an entirely different platform, and promising early data, but it must leapfrog memories that Isomorphic's private market investors don't share.
The bottom line: Biotechs keep going public despite a narrowed IPO window, but pricing remains an open question.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
dfa3ae0232· 2026-10-13 22:48 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前